Anticancer drugs: Next in line?

  title={Anticancer drugs: Next in line?},
  author={Peter Kirkpatrick},
  journal={Nature Reviews Drug Discovery},
556 | AUGUST 2002 | VOLUME 2 The success of the kinase inhibitor imatinib (Glivec) in the treatment of chronic myelogenous leukaemia — which is caused by the aberrant activity of the BCR–ABL tyrosine kinase — has given much encouragement for the development of other molecularly targeted therapies. As two reports in Cancer Cell… CONTINUE READING